TD Cowen analyst Charles Rhyee raised the firm's price target on CVS Health to $110 from $105 and keeps a Buy rating on the shares. The firm said they remain positive on CVS shares, as they view its raised 2026 as a conservative target, particularly in HCB, where management raised its guide for above expectations.
